You are here

zolbetuximab

FDA declines to approve Astellas' gastric cancer drug

Reuters

Tue, 01/9/24 - 09:39 am

Astellas' Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer

Xtalks

Mon, 07/17/23 - 06:54 pm

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

Drugs.com

Thu, 03/23/23 - 11:41 am

clinical trials

ASCO-GI 2023 – zolbetuximab opens up a stomach cancer niche

EP Vantage

Fri, 01/20/23 - 10:19 am

cancer of the gastro-esophageal junction

Astellas’ Phase III gastric cancer therapy trial meets primary endpoint

Clinical Trials Arena

Fri, 12/16/22 - 10:21 am

clinical trials

Astellas' $1.3B antibody strikes first in hot cancer field, extending survival in phase 3

Fierce Biotech

Thu, 11/17/22 - 10:37 am

clinical trials